Incenting Medicare STARS Clinical Health Measures: Evaluation of Part C HEDIS Measures by Kus, Martin





Background:  Medicare Advantage (MA) health Plans provide health insurance to a large portion 
of Medicare recipients.  Since passage of the Affordable Care Act, MA Plans have received 
substantial bonus payments based on their STAR rating, a measure of the quality of health care 
delivered by the Plan.  Part C of the Healthcare Effectiveness Data and Information Set (HEDIS) 
provides the clinical measures used to assign a STAR rating to the clinical performance of a MA 
health care Plan. 
Objective:  To evaluate the clinical measures listed in Part C of the HEDIS set to determine 
which measures would be best incentivized by a MA Plan in physician contracts. 
Methods:  The measures listed in Part C of the HEDIS data set were assessed to identify those 
with the potential to change physicians’ practice towards a higher STAR rating.  Eight measures 
were selected: breast cancer screening, colorectal cancer screening, osteoporosis 
management, diabetic eye exam, diabetic kidney disease monitoring, diabetic glucose control, 
blood pressure management, and rheumatoid arthritis (RA) management.  Individual measures 
were evaluated from the framework of the relevant stakeholder perspectives involved in 
performance of the measure: the patient, the insurance provider, the physician, and society.  
Result tables were used to report each measure’s performance and feasibility for physician-
contract incentives by each of the four relevant perspectives.  Each clinical measure was 
assigned a score based on its performance within the four selected perspectives.   
Results:  Of the eight relevant clinical measures of the Part C HEDIS data set, blood glucose 
control and RA management offered the greatest benefit to the patient based on the magnitude 
of improved health and avoidance of disease complications.  Diabetic kidney disease 
management was found to be the most favorable candidate from the insurer’s perspective 
owing to the low cost of testing and treating, while avoiding expensive complications.  The 
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physicians’ perspective received most benefit from diabetic eye and kidney disease measures 
due to the absence of significant barriers in completing the measure and the ease of reporting 
measure completion.  Societal benefits were greatest in colorectal cancer screening based on 
their ability to both reduce a significant societal disease burden and the potential to improve 
health care disparities. 
Conclusion:  This evaluation of the clinical measures of Part C HEDIS data plan found that 
diabetic kidney disease monitoring benefitted all stated perspectives and is a good measure to 





















I would like to thank the faculty of the Gillings School of Global Public Health at the University of 
North Carolina – Chapel Hill and the faculty of the Occupational and Environmental Medicine 
Division at Duke University for their collective support in this project. 
 
I am thankful for the mentorship provided by my 1st and 2nd readers, Dr. Lori Carter-Edwards and 
Dr. Vivek Nanda.  Dr. Carter-Edwards’ experience with program planning and evaluation was 
instrumental in this project’s focus and organization.  Dr. Nanda sacrificed many hours away from 
his job at Blue Cross / Blue Shield, North Carolina to meet with me to discuss the complex nature 
of this topic.  I thank, also, Dr. Brian Caveney for his mentorship and support in allowing me 
access to the Blue Cross / Blue Shield staff in an effort to familiarize me with this industry. 
 
I would like to give special thanks to the faculty of the Public Health Leadership Program: Dr. Sue 
Tolleson-Rinehart for her inspiring advocacy of public health policy and good writing, Dr. Russel 
Harris for teaching me to critically appraise scientific literature and rigorously evaluate public 
policy initiatives, and Dr. Anthony Viera for opening my eyes to the value of prevention in public 
health and for his leadership and example as a true physician scholar.   
 
 
This paper is dedicated to my wife, Celesta Kus, the coolest girl I know.  Her support and love 
was key in allowing me a rewarding and successful year at UNC.
  Kus 
iv 
 
Table of Contents 
 
Preface  
 Master’s Paper Abstract i 
 Acknowledgements iii 
 List of Tables and Figures v 
   
Original Manuscript – Incenting Medicare STARS Clinical Health Measures: 
Evaluation of Part C HEDIS Measures 
 
 Introduction 1 
 Methods 3 
 Results 5 
 Discussion 25 
 References 29 
 Tables and Figures 38 
   
Appendix – Limited Systematic Review: Are HEDIS Measures for Diabetes  
Cost-Effective? 
 
 Introduction 49 
 Methods 51 
 Results 56 
 Discussion 61 
 References 64 
 Tables and Figures 66 
  Kus 
v 
 
List of Tables and Figures 
 
Original Manuscript 
Figure 1: The Domains of Part C HEDIS Measures 38 
Table 1: Part-C Clinical HEDIS Measures 39 
Table 2: Summary of C01 – Breast Cancer Screening 40 
Table 3: Summary of C02 – Colorectal Cancer Screening 41 
Table 4: Summary of C12 – Osteoporosis Management 42 
Table 5: Summary of C13 – Diabetic Eye Exam 43 
Table 6: Summary of C14 – Diabetic Kidney Disease Monitoring 44 
Table 7: Summary of C15 – Diabetic Glycemic Control 45 
Table 8: Summary of C16 – Blood Pressure Control 46 
Table 9: Summary of C17 – Rheumatoid Arthritis Management 47 
Table 10: Results Summary 48 
 
 
Appendix – Limited Systematic Review  
Appendix Table 1: Current HEDIS Measures for Diabetes 50 
Appendix Table 2: PubMed/MEDLINE and Cochrane Library Search Terms 52 
Appendix Table 3: Inclusion/Exclusion Criteria for Studies of HEDIS Cost-
Effectiveness 
53 
Appendix Figure 1: PRISMA Systematic Review Flow Chart 66 
Appendix Table 4: Characteristics of Included Studies 67 
Appendix Table 5: Findings from Review of Included Studies of Cost-
Effectiveness of HEDIS Measures for Diabetes 
69 




Evaluation of Effectiveness of Clinical HEDIS Measures for Medicare Advantage 
 
Introduction 
 Since the 1970s, Medicare beneficiaries have been able to choose to receive their 
health benefits through private health plans instead of directly, through “Original” Fee-for-
Service Medicare.  This program was named Medicare Choice by the Balanced Budget Act of 
1997 and is currently known as Medicare Advantage (MA) since the Medicare Prescription 
Drug, Improvement, and Modernization Act of 2003.  Enrollment in these plans has steadily 
increased, tripling since 2004 from 5.3 million enrollees to 17.6 million today.  Currently, 31% of 
all Medicare beneficiaries obtain their health care benefits through Medicare Advantage Plans.1 
 The Centers for Medicare and Medicaid Services (CMS) hold that private health 
organizations delivering MA health services are accountable for the care they provide their 
enrollees.2  Thus, in 2007, a STAR ratings system was established for MA Plans as a consumer 
tool intended to help enrollees choose from competing health Plans that offer MA.  CMS 
asserted that research supported the use of symbols, such as Stars, as a valuable tool for 
consumers in determining the relative value of summary quality measures in their selection of 
Plans and providers.3  Since then, a STAR rating classification system has been used to grade 
the health services provided by to Medicare beneficiaries by MA plans. 
In 2012, under provisions of the Affordable Care Act (ACA), the STAR ratings began to 
be used to adjust payments to MA health plans.  Thus, the stated purpose of the STAR ratings 
system has been adjusted.  Whereas initially it was intended to help consumers choose the best 
MA plan for them, today it both provides quality information to consumers and determines MA 
quality bonus payments.3,4  The payment structure has also changed.  Initially bonus payments 
were awarded to MA Plans who receive four or more STARS based on threshold performance 
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measures.  Today, bonuses are based on a MA organization’s measures as they deviate from 
the mean, regardless of actual performance data or improvement.  Plans that outperform their 
competitors receive higher star ratings and, thus, more bonus payments; plans that perform 
poorly forfeit bonus payments as a result of low star ratings.4,5   
In an effort to improve their overall STAR rating, some MA plans have opted to 
financially incent participating physicians towards a clinical practice model which helps improve 
performance on HEDIS measures.6,7 As it is not financially feasible to incentivize physicians 
towards all HEDIS measures, care must be taken in choosing which measures to pursue.  A 
brief overview of the makeup of STARS measures is provided to describe its structure. 
 Medicare STAR ratings are based on performance measure data collected from five 
sources which provide information about the general health status of beneficiaries, patients’ 
experience of care, complaints and disenrollment, pharmacy use, and quality of care.  The 
source responsible for quality of care information is the Healthcare Effectiveness Data and 
Information Set (HEDIS).  This set is a list of performance measures that assess an MAO’s 
clinical effectiveness, accessibility to members, and resource utilization.3 
Medicare HEDIS measures are developed and managed by the National Committee for 
Quality Assurance (NCQA).  They are selected and shaped to be used for “comparison among 
health care systems, not measures for quality improvement.”8  The attributes used in selection 
are relevance (meaningful, clinically important, cost-effective), scientific soundness (evidence 
based, valid, accurate), and feasibility (measurable).8    
The STARS HEDIS measures are divided into two domains: Part C and Part D.  Part D 
measures evaluate pharmacy benefits; those of Part C evaluate the clinical realm.  There are 32 
Part C HEDIS measures that assess clinical performance.  They are divided into 5 domains: 
staying healthy, managing chronic diseases, member experience, complaints and changes in 
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health care performance, and health plan customer service.  These are presented in Figure 1.  
Of these, eight are chosen for evaluation based on their potential for a clinical health benefit 
related to an outpatient office visit (Table 1). 
The purpose of this paper is to evaluate the HEDIS Part C clinical measures in order to 
help determine which would be best incentivized in a physician contract.  Whereas cost-
effectiveness factors in measure selection, other factors can be considered.  First, the degree of 
health benefit to a patient which results from achieving a HEDIS measure is important.  All 
things being equal, incentivizing a measure which greatly improves health is preferable to one 
that is less beneficial.  Further, considering the barriers encountered by the physician in pursuit 
of a HEDIS measure differentiates which would be more or less likely to succeed.  Lastly, the 
degree to which a HEDIS measure improves societal health or decreases socioeconomic (SES) 
disparities is a significant factor to consider.  These various perspectives will be used as an 
evaluation tool in helping determine which HEDIS Part C clinical measure should be incented.  
 
Methods 
No validated evaluation system or tool exists for this type of analysis.  The Part-C HEDIS 
measures identified previously as “clinical” will be individually evaluated.  These include: breast 
cancer screening; colorectal cancer screening; osteoporosis management; diabetic retinopathy 
care; testing for diabetic nephropathy; diabetic glycemic control; hypertension control; and 
treatment for rheumatoid arthritis.  This appraisal will include the perspective of the various 
stakeholders involved in the performance of each individual HEDIS measure.  The relevant 
perspectives include that of the patient, the MA insurance provider (“Plan”), the physician, and 
society.   
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After describing the specific guidelines and metrics involved in achieving the HEDIS 
measure, it will be assessed from the perspective of the patient.  A literature review will examine 
the scientific basis of the NCQA’s decision to choose the HEDIS measure and, if appropriate, 
the recommendations of the U.S. Preventive Services Task Force (USPSTF).  The measure will 
be examined for magnitude of disease burden involved, evidence of health benefit purported to 
result from compliance with the guideline, and the magnitude of that benefit.  Lastly, the 
measure will be examined for any harms that may result from its implementation. 
The MA insurance plan’s perspective will begin with an assessment of the financial 
burden that the Plan will be responsible for.  An evaluation of available cost-benefit data for the 
measure will follow.  As the cost of health maintenance is seldom singular, the required 
frequency of the costs will be taken into account.  Long-term benefits will also be considered to 
examine the potential of decreasing future healthcare expenditures and, equally important, the 
risk of increased future expenditures should the measure not be pursued. 
 The physician’s perspective in terms of the HEDIS measure will focus on the barriers 
and concerns a physician faces in completing the measure.  The ease with which the rate of 
measure completion can be monitored will also be considered as a factor in deciding which 
measures can be incentivized. 
 Finally, the societal perspective of the measure will be examined for its ability to 
improve public health and lessen the disease burden of the population.  The presence or 
absence of SES and racial disparities in the applicable disease process will be described in 
order to identify a potential to improve such disparities.  
 The results of this “perspectives” analysis of each clinical HEDIS measure will be 
summarized in light of its potential to improve its corresponding health burden for each relevant 
stakeholder and serve as a viable measure for contract incentives.  The individual measures will 
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also be compared against each other by the degree of benefit for each perspective.  A score 
ranging from 1-5 will be assigned to each measure.  1 signifying a poor choice for contract 
incentives, 5 signifying strong evidence in favor of physician-contract incentives. 
 
Results 
Breast Cancer Screening 
 HEDIS Measure C01: Percent of female plan members aged 50-74 who had a 
mammogram during the past 2 years. 
Patient Perspective 
 Screening for breast cancer remains a controversial topic with several differing 
guidelines published by professional organizations.  The American College of Obstetricians and 
Gynecologists offers the most conservative screening strategy.  It recommends annual 
mammography for all women, beginning at age 40.9  The American Cancer Society 
recommends annual screening for women aged 45-54 transitioning to biannual mammography 
for women 55 or older.10  The USPSTF recommendation closely resembles the current HEDIS 
measure.11  Despite the various screening recommendations, evidence supports the USPSTF 
and HEDIS guidelines due to a mortality benefit for screening women aged 50-74 with no 
corresponding benefit to those younger or older.12  Similarly, a review of 5 trials showed a 29% 
breast cancer mortality reduction in women aged 50-69, finding none for women between 40 
and 49 years of age.13 
 Significant patient harms identified in breast cancer screening are over-diagnosis and a 
high false positive rate.14  Over-diagnosis is the detection of a tumor with a low-probability of 
being or progressing to clinical symptoms or death over a patient’s lifetime.  Both over-diagnosis 
and false positive findings result in significant psychological stress to patients as well as 
  Kus 
6 
 
unnecessary surgical biopsies and chemotherapy treatments.  A recent 25-year review of breast 
cancer incidence found a 22% rate of overdiagnosis.15 
Insurance Provider 
 Screening for breast cancer is a significant financial burden costing an average of $266 
per mammogram.16  In the US, 50 million screening mammograms are performed every year 
totaling more than $7 billion anually.17   
Cost-effectiveness analysis supports the current HEDIS guidelines stating that strategies 
which begin screening at age 40 are very cost-ineffective while screening biannually from ages 
50 to 64 reduce mortality at 7.8%, costing $18,999 per additional life year.18 
Physician 
 Physician compliance is a barrier to appropriate screening women for breast cancer.  
Although compliance rates are increasing, they have historically been as low as 57% due 
primarily to physicians’ inaccurate information about the health benefits of mammography.  Poor 
consensus from the various agencies that publish breast cancer screening recommendations 
served to further isolate physicians who already had difficulties accepting the evidence for 
mammography.19  Another study confirms these barriers, reporting that 29% of physicians 
believed annual mammography in women older than 50 is too frequent, 16% believed that 
screening was unnecessary in asymptomatic women, and 12% believed it less important in 
women without a family history of breast cancer.20 
 Identifying compliance with the current guidelines is easily accomplished by the 
insurance plan through monitoring of submitted insurance claims data, making this guideline 
easy to measure and incentivize in contracts. 
. 




 The benefits of breast cancer screening from the perspective of the community and 
society is complex.  The mortality benefit from the appropriate use of mammography is 
unquestionably a valued societal benefit despite its poor cost-effectiveness.  As the incidence of 
breast cancer is higher among African-American women, this measure has the potential to 
decrease this disparity in health by targeting the African American community and benefitting 
this population more, proportionally.21  These benefits should be in perspective of the financial 
burden that this measure represents for the entire population. 
Colorectal Cancer Screening 
 HEDIS Measure C02: Percent of plan members aged 50-75 who had appropriate 
screening for colon cancer. 
Patient 
 This HEDIS measure closely resembles the USPSTF recommendation for colon cancer 
screening, beginning at age 50.22  According to the USPSTF, screening can be accomplished 
with high-sensitivity fecal occult blood testing (FOBT) of 3 consecutive stool samples annually, 
flexible sigmoidoscopy every 5 years with fecal occult blood testing every 3 years, or 
colonoscopy every 10 years if results are normal.   
 FOBT is safe, convenient to patients who can perform the test at home, and effective.   
A Cochrane review shows that FOBT reduced the relative risk of death from colon cancer by 
16%.23  Flexible sigmoidoscopy reduces the relative risk of mortality by 28%, of the incidence of 
colon cancer by 18%, and the incidence of left sided colon cancer by 33%.24  Colonoscopy 
carries an absolute risk reduction of mortality of 60% and incidence of cancer by 17%.25 
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 Unlike FOBT, flexible sigmoidoscopy and colonoscopy are both invasive procedures 
which can be barriers for patients.  In a mixed-method analysis, the greatest identified barriers 
were fear of the procedure and the bowel preparation required beforehand.26  The barriers 
identified to be less prevalent are low self-worth, “para-sexual” sensitivities, fatalism, negative 
past experiences, and skepticism about the financial motivation behind the screening.   
 Colonoscopy and flexible sigmoidoscopy differ from FOBT in that they bear a risk of 
harm.  A recent USPSTF systematic review reported 2 to 5 bowel perforations per 10,000 
colonoscopies and 5-14 major hemorrhagic events per 10,000 colonoscopies.27 
Insurance Provider 
 According to Consumer Reports, the average cost of colonoscopy in the US is $1,100 
ranging from $800 - $3160.  Flexible sigmoidoscopy costs an average of $740 while FOBT 
costs only $10.28  The outpatient visits for the referral and the review of the results are not 
included in these figures.  These costs carry special significance for MA plans not only because 
they are substantial and recurring, but also because the ACA requires that the entire cost of 
screening be covered with without a co-payment.29   
Although these costs are substantial relative to many medical tests, cost analyses have 
concluded that, when compared to no screening, all colon cancer screening strategies are cost-
saving.30  An incremental cost-effectiveness analysis of the three screening modalities yields no 
single optimal screening strategy.  While FOBT testing is fairly inexpensive compared to 
colonoscopy, factors such as the frequency of testing for FOBT and its inferior sensitivity for 
colon cancer serves to make them equal in a cost-benefit analysis.  There is consensus, 
however, that stool DNA testing, computed tomographic colonography, and capsule endoscopy 
are not yet cost-effective compared to the screening tests currently recommended.31 
Physician 
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 The barriers physicians encounter in successfully completing colon cancer screening 
include deferment of testing to a later time due to psychosocial issues, impeding or more 
pressing comorbid medical illness, considering screening a low priority during a short outpatient 
office visit, and a perception that a patient may lack  willingness to seek preventive care.32  Lack 
of local or accessible gastroenterologists has also been noted in remote or rural areas.33 
 Identifying compliance with colon cancer screening recommendations is accomplished 
easily by the insurance plan through monitoring of submitted insurance claims data, making this 
guideline easy to measure and incentivize in contracts. 
Society 
 In light of the significant mortality benefit conferred by colon cancer screening, the ability 
to decrease the incidence of cancer, and its cost-effectiveness, colon cancer screening 
strategies appear to significantly benefit the community and the entire healthcare system.  In 
fact, according to a randomized trial from Nottingham, England conducted between 1981 and 
1991, patients with a positive colon cancer screening test lived longer than those with a 
negative test due to appropriate treatment of the malignancy, incidental identification of 
comorbid illnesses during the workup, and greater engagement with health services.34 
 Although the rates and mortality of colon cancer has been decreasing over the past 2 
decades, the incidence of colon cancer remains significantly elevated in African-American 
men.35  An increased focus on colorectal cancer screening in this minority group can serve to 
decrease racial disparities and promote improved health equality. 
  Osteoporosis Management in Women who had a Fracture 
 HEDIS Measure C12: Percent of female MA plan members aged 67-85 who broke a 
bone and got screening or treatment for osteoporosis within 6 months. 




 The USPSTF recommendations screening asymptomatic women for osteoporosis 
beginning at age 65 with dual-energy x-ray absorptiometry (DEXA).36  Although this HEDIS 
measure is not a screening strategy, a comparison to the USPSTF recommendation shows it to 
be more cost-effective.  The age of testing is similar for both the USPSTF recommendation and 
HEDIS measure.  The population tested by the HEDIS measure, however, has a significantly 
higher pre-test probability of disease (the presence of an existing fracture makes osteoporosis 
more likely).  The rate of positive findings will be higher in the HEDIS population making it cost-
effective. 
Treating osteoporosis and increasing bone marrow density reduces future fractures.  
The reduction in fractures is the target benefit of osteoporosis testing and treatment as it can 
significantly improve a person’s quality-of-life and health.  A recent meta-analysis demonstrates 
that bisphosphonate therapy, a common osteoporosis oral treatment, has a strong, dose-
dependent, linear relationship to increased spine bone-marrow density compared to placebo.37  
A meta-analysis from China found that intravenous bisphosphonate therapy increases bone 
density by a factor of 2.98, reducing the fracture rate by 32%.38  Treatment with a combination 
of several available osteoporosis treatment medications offers the greatest patient benefit, 
decreasing the relative risk of vertebral fractures by 40-60% and that of non-vertebral fractures 
by 60-80%.39 
These benefits, however, must be weighed against the potential harms of treatment for 
osteoporosis.  Oral bisphosphonate therapy causes gastrointestinal symptoms that cause as 
many as 20% women to discontinue its use.40  Intravenous bisphosphonates therapy causes a 
significant flu-like illness in 30% of subjects and it has the potential to be severely nephrotoxic.41 
Insurance Provider 
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 Because testing is infrequent, an average price of $132 for a DEXA scan, with a range 
from $150 - $250 is a reasonable cost in detecting osteoporosis following a fracture.42  Cost-
effectiveness analyses support routine screening of women aged 55-80, finding it superior to not 
screening.43  As noted above, the HEDIS measure is very likely more cost effective than a 
screening strategy.   
Treatment, however, is very expensive.  Bisphosphonate therapy alone costs $125 - 
$148 per month for brand name drugs, and $38 - $70 for generics.42  Cost-benefit analyses 
support treating women aged 70 or greater while recommending against treating women under 
50 years of age.  Whether it is cost-effective to treat women between ages 50 and 69 is 
unclear.44  The total cost of osteoporosis treatment is significant at over $5 billion to treat all 
eligible women.  This strategy would reduce fracture rates by 35% with an annual cost of a 
quality year (QALY) gained of $66,722.45 
Physician 
 One of the barriers that physicians face in testing for and treating osteoporosis is the 
safety concern of the treatment drugs.  There is no universal clinical treatment guideline to 
follow due to the uncertainty of bone experts about the management of osteopenia, frequency 
and timing for follow up DEXA scans, and the appropriate amount of calcium and Vitamin-D to 
prescribe.  Making treatment decisions in the face of this kind of uncertainty and fear of harms is 
a difficult undertaking made more difficult when treating patients with significant comorbidities 
which make harms of treatment more likely to occur.46   
Physicians also report that osteoporosis screening and treatment is not always a priority 
in a short outpatient visit with older women who have many medical problems.47  
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 Tracking progress and compliance with this osteoporosis measure is accomplished 
easily by the insurance plan through monitoring insurance claims data, making this guideline 
easy to measure and incentivize in contracts. 
Society 
 A considerable amount of variation in the incidence of testing for osteoporosis following 
fractures between different races and persons of differing SES background.  African-American 
and Hispanic women are less likely to receive osteoporosis testing both before and following a 
fracture when compared to white women.48  The results are similar for women with lower 
education and income levels when compared to more women from a higher SES background. 
 The disease burden placed on the population by osteoporosis is significant.  The 
monetary component to fracture care in women with osteoporosis includes medical treatment 
and rehabilitation which costs $17 - $20 billion annually.49 The non-monetary burdens include 
family stress from caring for an aging and injured family member, and the risk of health 
deterioration that can occur when an elderly person is immobilized following a fracture. 
Diabetes Care – Eye Exam 
 HEDIS Measure C13: The percent of MA enrollees aged 18 – 75 with diabetes who had 
a retinal eye examination during the year. 
Patient 
 Diabetic retinopathy (DR) is the most frequent cause of blindness among adults.  During 
the first 20 years of disease, nearly all type-1 diabetics and 60% of those with type-2 have 
retinopathy.50  The severity of DR at baseline is also directly related to the incidence of 
proliferative retinopathy, the more advanced form of disease which involves of new and fragile 
blood vessels into the retina and vitreous.  The incidence of proliferative retinopathy is 30% in 
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those diagnosed before age 30, 24% in those requiring insulin who were diagnosed after age 
30, and 10% in those not requiring insulin.51 
 While the incidence of DR among diabetics with severe disease is high, the incidence in 
those with mild disease is significantly lower.  Patients with mild disease exhibit good glycemic 
control, older age, and no retinopathy on prior examinations.  They receive little benefit from 
annual screening examinations. These patients may benefit from screening every three years in 
light of the health care costs associated with screening and the frequency of other diabetic 
outpatient visits, which range from 8 – 12 visits per year.  Annual screening in this low-risk 
group increases 2-3 days of sight at a cost of $540 - $690 per patient.52  Despite this data and in 
the absence of other empirical data, all diabetics are recommended to be screened for DR 
every year.50 
 Except for the inconvenience of a screening outpatient appointment, no additional 
barriers or harms are identified to annual DR screening in diabetics. 
Insurance Provider 
 The national average cost of an eye examination is $114 but can cost as little as $50 at 
discount clinics and with contracted insurance rates.  Although biannual screening may be a 
more efficient allocation of resources, annual screening of diabetics is cost-effective leading to a 
small health benefit at a moderately additional cost compared to biannual screening.53 
Physician 
 The barriers identified to annual screening examinations were patients’ financial 
constraints and the inconvenience of another outpatient medical appointment added to the 
multiple annual visits expected of every diabetic patient.52,54  While some areas of the country 
reported long wait times for a diabetic eye examination, these were not found to be barriers to 
care. 
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 Tracking progress and compliance diabetic eye examinations is accomplished easily by 
the insurance plan through monitoring insurance claims data, making this guideline easy to 
measure and incentivize in contracts. 
Society 
 An economic review found that annual screening for DR in type-1 diabetics without 
retinopathy and every 6 months for those with identified disease was calculated to save 70,000 
– 80,000 person-years of sight, while saving $70 - $80 million annually in the US.55  For type-2 
diabetics, the savings were greater than 94,000 person-years of sight with a savings of over 
$250 million annually.56 
 The incidence of DR varies among racial groups.  A small study found that after 
controlling for A1C values, blood pressure, and gender, African-Americans had a significantly 
increased incidence of diabetic retinopathy compared to white patients (50% versus 19%).57  A 
Veterans Affairs study had similar findings.  After controlling for confounders, the incidence of 
DR was 36% in African-Americans, 29% in Hispanics, and 22% in non-Hispanic whites.58   
Conflicting evidence exists, however.  A cross-sectional analysis of 778 diabetics aged 45-85 
found that, despite the increased rates in African-American patients, race was not an 
independent predictor of DR.59  The independent predictors of DR were identified as longer 
duration of diabetes, higher fasting glucose levels, greater waist-hip ratio, and the use of insulin 
or other diabetic medications.  Regardless of the independent risk factors, a difference in 
diabetic retinopathy by race exists providing an opportunity to decrease this disparity with 
incentivized practice parameters. 
Diabetic Care – Kidney Disease Monitoring 
 HEDIS Measure C14: The percent of MA enrollees aged 18-75 with diabetes who had a 
kidney function test during the year. 




 Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) 
accounting for 50% of ESRD in the developed world.60  Diabetics are at increased risk for ESRD 
than non-diabetics with an odds ratio of 33.7 for insulin-dependent diabetics and 7.0 for non-
insulin dependent patients.  The resulting population-attributable risk of renal failure in diabetics 
is 42%.61 
 Despite the significantly increased risk of ESRD, pharmacologic therapy for diabetics 
has been shown to be extremely effective in reducing its incidence.  Specifically, therapy with 
angiotensin-converting enzyme (ACE) inhibitors significantly impedes progression to clinical 
proteinuria and ESRD.62  The Microalbuminuria Study Group found that 7.2% of patients on 
ACE inhibitor therapy progressed to proteinuria compared to 21.9% of those without.63 
 The barriers encountered by patients in diabetic kidney screening were late referral to 
nephrologists, old age, multiple co-morbidities, and lack of education and awareness among 
ethnic minorities.64  No harms of screening are identified. 
Insurance Provider 
 The purpose of screening diabetics for DKD is early identification and early treatment to 
prevent progression to ESRD.  The costs of caring for diabetics with ESRD is extraordinarily 
high.  For the Medicare population in 2011, DKD expenditures were nearly $25 billion.60  The 
cost of dialysis can be $500 per treatment and the typical regimen includes three treatments per 
week.  This amounts to $60,000 per year not including the cost of medications and vitamins.65 
 To contain these costs, annual screening helps identify early DKD, allowing for early 
treatment to combat disease progression.  Screening and treatment with ACE inhibitors has 
been shown to be very cost-effective, with a QALY of $7,900 - $16,500.66  According to a 
systematic review of the cost-effectiveness of ADA recommendations, screening was found to 
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be cost-effective but, more importantly, early identification of disease and treatment with ACE 
inhibitors was cost-saving.53 
Physician 
 Aside from the presence of co-morbidities or acute illnesses which may take precedence 
over addressing diabetic nephropathy screening in the setting of a short outpatient health visit, 
no specific barriers to physicians are identified.  Tracking and monitoring appropriate screening 
within a physician’s practice is easily accomplished through claims data. 
Society 
 Over the past two decades, the incidence of ESRD attributable to DKD has stabilized.  
The rates continue to rise among high-risk groups such as African Americans, Native 
Americans, and Hispanics.60  There is evidence that SES status is a significant factor, if not the 
primary factor, involved in this disparity.67  An evaluation of SES status in relation to diabetic 
kidney disease also notes that poor SES status is associated with poorer glycemic control and 
higher rates of complications, such as nephropathy.68 
Diabetes Care – Blood Sugar Controlled 
 HEDIS Measure C15: The percentage of diabetic MA enrollees aged 18-75 whose most 
recent HbA1c is greater than 9% or who were not tested during the measurement year. 
Patient 
 Euglycemia, a normal blood level of glucose in the blood, is the most important factor in 
the treatment of diabetes.  Intensive glycemic control has been shown to delay the onset of and 
to slow the progression of diabetic eye, kidney, and nerve complications.69  Poor glycemic 
control results in retinopathy, nephropathy, coronary arterial disease, cerebral arterial disease, 
and distal neuropathy.70  Diabetics with poor glucose control are also at risk for hearing 
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impairment, sleep apnea, fatty liver disease, dental disease, cognitive impairment, and 
depression.71  Diabetes can also be a heavy psychosocial toll which often results in diminished 
self-care, poor long-term glycemic control, and ultimately, increased long term complications. 
 According to the American College of Physicians, the goal of glycemic control should be 
as low as possible with minimizing risk of adverse events or significant inconvenience to the 
patient.  They recommend a target hemoglobin A1c (HbA1c) level of 7% for most, but not all, 
patients.72  For patients who exhibit difficulty in maintaining tight glycemic control without 
complications, such as hypoglycemia, an individualized HbA1c goal is recommended.  A recent 
retrospective study agrees with the personalized HbA1c goals for these patients, reporting that 
more than 20% of type 2 diabetics who are treated with intensive therapy nearly doubles the risk 
of severe hypoglycemia.73  In light of this evidence, the HEDIS HbA1C goal of less than 9% is a 
safe target to use clinically in glycemic control. 
Insurance Provider 
 Diabetes is a significant contributor to healthcare spending.  The US, home of 8% of the 
world’s diabetic population, is responsible for 50% of the world’s diabetes expenditures.74  The 
annual cost of diagnosed diabetes exceeds $245 billion, more than half of which is related to 
complications such as myocardial infarctions, stroke, ESRD, retinopathy, and foot ulcers.75  
Individuals with diabetes have medical expenditures 2.3 times higher than those without 
diabetes, averaging $13,700 per year.76 
 Intensive glucose control interventions in increases expenditures but has been shown to 
be very cost-effective due to its ability to halt or slow the development of complication.77  A 
similar analysis of intensive diabetic control reported the incremental cost per QALY to be 6,028 
UK pounds, a low figure compared to many other routine interventions.78 
Physician 
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 There has been concern about possible harms in select patients striving to achieve very 
conservative HbA1c goals, such as the 7.0% goal recommended by the ADA.79  The target 
HbA1c value identified in the HEDIS measure (9.0) is a safe and conservative goal, unlikely to 
cause adverse hypoglycemic events in diabetic patients.  
 Time and resource constraints encountered by a physician in the outpatient setting are a 
barrier to glycemic control in diabetics.  This barrier has been called “clinical inertia” or “benign 
neglect”, defined as overly cautious prescribing practices due to fear of side effects, 
underestimation of patient needs, failure to set clear treatment goals, or lack of encouragement 
to reach goals.80  Poorly organized disease planning or the absence of clearly defined treatment 
goals can also be a physician barrier in achieving glycemic control.  Where a proactive 
approach includes a treatment plan with milestones attached to future visits, an absence of 
planning threatens to forego education and the patient’s pursuit of health in favor of a patient’ s 
currently symptomatic illnesses or concerns.81 
 Tracking and monitoring HbA1c levels presents a possible difficulty in using this HEDIS 
goal as an incentive.  Today’s coding systems utilize the 10th Edition of the International 
Classification of Disease (ICD) codes.  The code for diabetes does not allow for a “controlled” or 
“uncontrolled” classification qualifier.  Using claims data received by the insurance provider may 
present a similar problem.  Whereas claims traditionally record only the completion of a test, 
tracking HbA1c levels would require adding the test results to the claim. 
Society 
 Minorities are disproportionately represented among the 25.8 million people in the US 
with diabetes.82  Native Americans make up 33% of diabetics, African-Americans represent 
12.6%, and Hispanics 11.8%.  Non-Hispanic whites, Asian-Americans, and Alaska natives 
represented the lowest proportion of the total, 7.1%, 8.4%, and 5.5% respectively.  Although 
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studies note that psychosocial differences are involved in racial diabetes prevalence, African 
Americans continue to have poorer glycemic control after controlling for these psychosocial 
factors.83 
Controlling Blood Pressure 
 HEDIS Measure C16: The percentage of MA members aged 18-85 with high blood 
pressure which was adequately controlled (<140/90 for members aged 18-59 and for those 
aged 60-85 with a diagnosis of diabetes; <150/90 for members aged 60-85 without a diagnosis 
of diabetes) during the measurement year. 
Patient 
 Hypertension is a significantly prevalent disease process in the US affecting 29% - 31% 
of the population.84  Despite increased awareness, treatment, and improvements in blood 
pressure control over the past few decades, only 50.1% of people with hypertension are 
controlled below the 140/90 target level.85  Poor blood pressure control is responsible for many 
significant complications such as heart failure, myocardial infarction, sudden death, and 
stroke.86  Hypertension is also the most important risk factor for intracerebral hemorrhage and a 
significant risk factor for kidney disease and ESRD.87,88 
 Treatment for hypertension includes many varied therapeutic options which, when used 
appropriately to control blood pressure, have been shown to reduce cardiovascular events by 
20% - 25%.89  Similarly, evidence shows that blood pressure control reduces cerebrovascular 
events by 42%.90  Despite the significant benefits of adequate blood pressure control, strict 
blood pressure control can result in adverse effects.  A large randomized trial of intensive blood 
pressure control reported an increase in the incidence of hypotension, syncope, bradycardia, 
arrhythmias, hyperkalemia, angioedema, and renal failure in patients receiving the intervention 
compared to standard therapy.91 
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 There are many barriers to hypertension treatment for patients.  Patients often discount 
the consequences of elevated blood pressure because they experience no symptoms from the 
disease process.  These beliefs affect patient’s motivation in achieving good control.  Daily 
activities, work, and family concerns are often higher priorities than outpatient visits and healthy 
lifestyle modifications, such as exercise.  Financial constraints can also affect a patient’s ability 
to purchase medications.  Beliefs that taking medications makes someone weaker or less 
healthy can affect treatment as much as the fear of medication side effets.92 
Insurance Provider 
 As approximately 76.4 million Americans have elevated blood pressure, treatment of 
hypertension is the most common reason for outpatient office visits and for the use of 
prescription drugs.84  As the population ages and obesity increases, the incidence and 
healthcare burden of hypertension is likely to grow, especially in persons older than 65 years of 
age.93 
 Stroke, hypertension, heart failure, and other cardiac diseases account for 17% of all 
medical spending in the US, amounting to $149 billion annually.  They account for 30% of all 
Medicare spending.  Of these four disease processes, hypertension is responsible for the 
greatest share of this spending in prescription expenditures.94 
 Under the HEDIS program, insurance carriers will likely find that improving the care of 
those with moderate hypertension is more cost effective than focusing on severe hypertension.  
Successful treatment of severe hypertension down to the recommended goal is more difficult 
and expensive than that of moderate hypertension.  A relaxed set of goals for persons with 
severe hypertension may rectify this unintended HEDIS consequence.95 
Physician 
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 Physicians face several barriers and difficulties in treating hypertensive patients.  One 
unique to hypertension treatment is relative difficulty in obtaining a diagnosis.  Whereas most 
disease processes can often be diagnosed with one set of test results, the diagnosis of 
hypertension requires multiple blood pressure measurements on different days, requiring repeat 
outpatient visits, some of which should occur outside the medical office setting.96  As 
hypertension is a mostly an asymptomatic disease process, compliance rates are often difficult 
to maintain creating another barrier for physicians to achieve their HEDIS goal.  In a cohort of 
nearly 200,000 hypertension elderly patients, nearly a quarter did not refill their hypertension 
medications.97 
 As mentioned previously, therapeutic inertia is a barrier to physicians in the treatment of 
hypertension.  For hypertension, therapeutic inertia is the failure of a physician to increase 
therapy for a patient already treated in response to poor blood pressure control.  This is 
becoming a common and recognized barrier to blood pressure control rates.98 
 Tracking and monitoring blood pressure levels may be difficult.  The ICD-10 code for 
hypertension does not allow for a “controlled” or “uncontrolled” classification qualifier.  As claims 
data are not submitted for blood pressure testing, another form of reporting must be established 
to follow blood pressure data. 
Society 
 Hypertension is a heavy burden on societal health.  In 2011, cardiovascular disease, 
often related to hypertension, accounted for nearly one-third of all deaths within the US.  Every 
day, more than 2,150 Americans die of cardiovascular disease, an average of one death every 
40 seconds.  A third of these deaths occurred before age 75, younger than the average life 
expectancy of 78.7 years.99   
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There is a significant difference in these death rates between racial groups.  The death 
rate for white males is 271.9 per 100,000, while that for African-American males is 352.4 per 
100,000.  The same rate for white women is 188.1 per 100,000, while that for African-American 
women is 248.6 per 100,000.99  A longitudinal study of more than 15,000 young adults in the US 
revealed that higher household income and being married were independently associated with 
better blood pressure.  The factors that were associated with poorer blood pressure were older 
age, male sex, African-American ethnicity, higher body mass index, greater waist 
circumference, smoking, and higher alcohol intake.100 
Rheumatoid Arthritis Management 
 HEDIS Measure C17: Percent of MA members with Rheumatoid Arthritis who were 
dispensed at least one anti-rheumatic drug. 
Patient 
 Rheumatoid Arthritis (RA) is a chronic, systemic, and inflammatory disorder which leads 
to destruction of joints and joint deformities.  Typically, “classic” RA begins with stiffness, pain, 
and swelling of the peripheral joints of the hands and feet, moving centrally as the disease 
progresses.101  However, patients demonstrate a wide variability in the pattern of joint 
inflammation, severity of symptoms, and the timing of RA exacerbations.102  Whereas most of 
the disease activity (joint inflammation) is treatable and reversible, inflammation can cause joint 
tissue erosion and other structural damage that may be both cumulative and irreversible.103 
 While the primary focus of the RA disease process is on articular tissue, 40% of patients 
develop extra-articular manifestations which can affect the skin, eyes, lungs, heart, kidney, 
blood vessels, salivary glands, central and peripheral nervous systems, and the bone 
marrow.104  Of note, RA brings a significant risk of coronary artery disease which may include 
heart failure and atrial fibrillation.105 
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 Disease Modifying Anti-Rheumatic Drugs (DMARDs) have been the mainstay of RA 
treatment since the 1970s.  Although their effectiveness varies among individuals, they have 
been shown to decrease inflammation in RA patients and halt radiographic progression of 
articular disease.106  Significant toxicities are associated with DMARDs and other medications 
commonly used to treat RA.  They suppress the immune system, increasing the risk of serious 
infections, and negatively affect the healing process.107  Bacterial infections, especially 
pneumonia and skin infections, increase 2-4 fold with the use of RA medications.  Tuberculosis 
reactivation, systemic fungal infections, and viral infection reactivations have all been observed 
to occur from treatment of RA.108 
 The barriers and difficulties commonly encountered by patients with RA patients are 
difficulty in recognition of disease and medication compliance.  Joint pain is only one of the 
several varied manifestations in which RA can initially present.  Also, considering the ubiquitous 
nature of “joint pain”, it is often difficult for someone suffering from new-onset RA to make an 
appointment with a physician in a timely manner.109  Medication adherence is another significant 
problem among RA patients.  Although all treatable disease processes suffer from some level of 
medication non-compliance, the medication adherence rates for RA have ranged from 30% - 
80%.110 
Insurance Provider 
 The aggregate economic burden of RA in the US is $19.3 billion annually.  Using this 
figure, the cost that each patient individually accrues on average is $14,900 annually.  The 
portion of this expense that involves medical visits and prescriptions, the portion insured by the 
MA plan, is $8.4 billion or 44% of the total.111  Medication costs represent a large portion of the 
RA expense to an insurer.  A recent article reported that several RA drugs have steeply 
increased in price.  The price of Enbrel, a medication commonly used in RA treatment, has risen 
by 80.3% since 2013 and now exceeds $4,000 for a 30-day supply.  The price of Humira also 
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rose by 68.7% to $3,700 for a monthly supply while that of Xeljanz rose by 44.3% to over 
$3,100 per month.112 
 An analysis of the cost of RA medications noted that if the definition of cost-effectiveness 
is set at 35,000 UK pounds per QALY, none of the medications appear to be cost-effective.  If 
the threshold was lifted to 50,000 or 100,000 UK pounds per QALY, some of the medications 
may be cost effective.113  A related editorial claims that the economic consequence of failing to 
slow RA progression far outweigh the costs of any currently available therapy.  The author 
recommends that not to focus on the cost of the medications but on the degree to which they 
are successful in halting progression of RA.114 
Physician 
 Like their patients, physicians treating persons with RA also deal with the problem of 
non-compliance.  A review of RA patients reported a compliance rate of 80.3%.115  The most 
common reasons cited for poor adherence to the RA medication regimen were side effects and 
the fear of side effects.  Compliance was worst among younger and more active RA patients 
with a higher income level.  Factors that correlated with better compliance were more frequent 
rheumatology appointments, satisfaction with health care provider, and sufficient education 
about the treatment of RA. 
 Tracking a physician’s compliance with the RA treatment HEDIS measure is easily 
accomplished through claims data. 
Society 
 As noted previously, the total annual cost of treating RA patients is $19.3 billion, each 
patient costing $14,900 annually.  While the direct medical costs are covered by the MA plan, 
the indirect costs, which include premature mortality, the deterioration in quality-of-life, and the 
cost of caregiving, are borne by the society.111  All MA plans cover at least one DMARD.  The 
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majority of plans require a co-payment from the insured at an average of 29.5% of the total cost 
of the medication, rather than a fixed dollar co-payment.  This out-of-pocket cost ranged from 
$2,712 - $2,774 annually before reaching the catastrophic phase of coverage, after which the 
insured is responsible for 5% of the cost.116 
 Evaluation of the disparities in RA prevalence revealed no race-related data but showed 
a SES difference.  Persons without a university degree had an increased risk of RA compared 
to those with a degree (relative risk of 1.4).117  In patients with established RA, those with a low 
SES status suffer worse disease activity, physical health, mental health, and quality-of-life 
compared to RA patients with a high SES status.  This difference decreases over time.118  
These differences are influenced by age, gender, marital status, and work disability.  SES status 
is also associated with physical limitations resulting from RA and are predictive for work-related 
income reduction, reduced transport mobility, and the development of social dependency.119 
 
Discussion 
 In evaluating the clinical HEDIS measures for potential physician incentives in contracts 
with MA plans, each of the measures was examined from the perspective of the relevant 
stakeholders involved in measure completion.  The vantage points considered were that of the 
patient, the insurance carrier, the physician, and society.  The scores applied to each 
perspective of a HEDIS measure was based on its feasibility to be incented in a physician 
contract as seen in Table 2 – Table 9.  The scores were collected for comparison between 
measures in Table 10. 
 From the patient’s perspective, all measures scored well and are possible candidates for 
use as incentives except one: breast cancer screening.  Although the clinical guidelines used in 
the HEDIS measure resemble other published recommendations, published literature reveals a 
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significant risk of harms to a large portion of the female population from screening.  The harms 
identified are over-diagnosis and a significant false positive rate, both of which serve to supply a 
large emotional health burden on women who test positive by mammography.  They also 
significantly burden the healthcare system in unnecessary expenses of subsequent medical 
evaluation and treatments.  The measures that stood out as exceptionally good candidates for 
contract incentives were diabetic glycemic control and RA management.  From the perspective 
of the patient, achieving better glycemic control benefits a patient’s quality of life and health, 
primarily by avoiding the serious cardiovascular, renal, ocular, and nervous complications of 
diabetes.  Similarly, the early identification and treatment of RA has the potential to greatly 
decrease RA patient’s future disability resulting in decreased economic/occupational losses and 
improved quality-of-life. 
 The insurance provider’s perspective yielded only one measure that performed well.  
The HEDIS measure for DKD monitoring revealed that both testing and treatment options were 
cost-effective.  Successful treatment has the potential to greatly reduce future costs to MA plans 
by avoiding ESRD and the accompanying expenses of dialysis.  The HEDIS measure that 
performed worst from this perspective was the diabetic eye exam.  The reasons for the low 
assessment is the annually recurring expense of eye examinations and the cost of laser 
treatment, both of which are highly cost-ineffective. 
 The HEDIS measures that performed best in from the physician’s perspective were 
diabetic eye exam and DKD monitoring.  Both of these measures scored well due to their ease 
of tracking mechanisms for HEDIS measure completion through insurance claims data.  They 
also lacked any significant physician barriers towards successful HEDIS measure achievement.  
The least advantageous measures to physicians were osteoporosis management and blood 
pressure control.  Both posed significant barriers to a physician’s ability to meet treatment goal 
thresholds due to historically high patient non-compliance rates. 
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 All clinical HEDIS measures showed physician contract potential from the societal 
perspective.  The benefits to the society were either financial, decreasing the vast expenditures 
of endemic rates of complications, or in the realm of health, decreasing to the total societal 
burden of disease (prevalence).  For most measures, the disease processes in question 
demonstrated prevalence rates with inequalities in either racial or SES, making them candidates 
for decreasing health disparities.  Colorectal cancer screening performed best from the societal 
perspective due to the significant mortality benefit and the ability to target for the racial subgroup 
most affected by colon cancer screening, African-American men. 
 The clinical HEDIS measure that showed most potential in contract incentives was 
diabetic DKD monitoring.  From every examined perspective, it conferred many benefits and few 
harms.  For patients, it identifies early DKD for which an effective treatment exists that can 
curtail many life-threatening complications.  Both screening and treatment options were cost-
effective and successful in reducing the vast expenses of ESRD, which are attractive factors to 
MA insurers.  Physicians encounter few barriers and an easy method for compliance tracking.  
Lastly, there are substantial financial and disease-burden benefits to society in reduction of 
ESRD incidence. 
 This evaluation has several limitations.  The first is the absence of a validated evaluation 
tool for use in analyzing clinical HEDIS measures.  The format and tool used here is the product 
of many meetings and discussions with insurance industry experts who are active in the 
insurance sector.  The second is the absence of an objective scoring system which controls for 
inter-person variability.  Despite the subjective scoring system used her, however, the measures 
that either outperformed or fell short of the average would likely have settled there even with a 
validated scoring system.  Lastly, this analysis lacked a systematic review system for each 
subject, relying greatly on a manual search of the PubMed/MEDLINE literature, UpToDate, 
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published review and editorial articles, and their references.  Thus, there exists a possibility that 
relevant factors have been overlooked and not considered. 
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C01 Breast Cancer Screening  
C02 Colorectal Cancer Screening  
C03 Annual Flu Vaccine  
C04 Improving or Maintaining Physical Health  
C05 Improving or Maintaining Mental Health  
C06 Monitoring Physical Activity  
C07 Adult BMI Assessment  
Managing Chronic Diseases 
C08 SNP Care Management  
C09 Care for Older Adults – Medication Review  
C10 Care for Older Adults – Functional Status  
C11 Care for Older Adults – Pain Screening  
C12 Osteoporosis Management  
C13 Diabetes Care – Eye Exam  
C14 Diabetes Care – Kidney Disease  
C15 Diabetes Care – Sugar Control  
C16 Controlling Blood Pressure  
C17 Rheumatoid Arthritis Management  
C18 Reducing the Risk of Falling  
C19 Plan All-Cause Readmissions  
Member Experience 
C20 Getting Needed Care  
C21 Getting Care Quickly  
C22 Customer Service  
C23 Rating of Health Care Quality  
C24 Rating of Health Plan  
C25 Care Coordination  
Complaints and Changes in Health 
Care Performance 
C26 Complaints about the Health Plan  
C27 Members Choosing to Leave the 
Plan  
C28 Beneficiary Access and 
Performance Problems  
C29 Health Plan Quality Improvement  
Health Plan Customer Service 
C30 Plan Makes Timely Decisions 
about Appeals  
C31 Reviewing Appeals Decisions  
C32 Call Center – Foreign Language 
Interpreter and TTY Availability  
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C01 Breast Cancer Screening 
C02 Colorectal Cancer Screening 
C12 Osteoporosis Management 
C13  Diabetes Care – Eye Exam  
C14  Diabetes Care – Kidney Disease  
C15  Diabetes Care – Sugar Control  
C16  Controlling Blood Pressure  
C17  Rheumatoid Arthritis Management  
* The term “clinical” refers to the measures which both affect a 
patient’s health and is addressed primarily in a physician 
outpatient visit. 
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Table 2: Summary of C01 – Breast Cancer Screening 
Perspective Summary of Findings Grade* 
Patient Measure supported by good clinical evidence.  Significant risk 
of harm from over-diagnosis and high false positive rate leading 
to unnecessary procedures and treatments. 
2 
Insurance Provider Screening is a significant and recurring financial burden.  
Moderately cost effective although not cost saving. 
2 
Physician Conflicting screening guidelines confuse clinicians about the 
benefits of screening and their proper utilization.  Measure 
completion is easily tracked through claims data. 
3 
Society Mortality benefit despite financial cost of screening to society.  
A racial difference in prevalence of breast cancer exists which 
may be a target for screening implementation. 
4 
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Table 3: Summary of C02 – Colorectal Cancer Screening 
Perspective Summary of Findings Grade* 
Patient Based on good clinical evidence.  Significant mortality benefit.  
FOBT is convenient and non-invasive.  Colonoscopy and 
flexible sigmoidoscopy are invasive and pose a small risk of 
harm 
4 
Insurance Provider Can be expensive and is a frequently recurring cost.  Generally 
considered cost-effective 
3 
Physician Physicians do not prioritize colon cancer screening highly.  
HEDIS measure completion is easily monitored by claims data. 
3 
Society Effective in decreasing mortality and decreasing incidence of 
colon cancer, and cost-effective.  More prevalent in African-
American men. 
5 
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Table 4: Summary of C12 – Osteoporosis Management 
Perspective Summary of Findings Grade* 
Patient Based on solid clinical evidence.  Similar to the screening 
recommendations of the USPSTF.  Treatment offers strong 
clinical benefits.  Some rare and moderate side effects. 
4 
Insurance Provider Testing is an infrequent expense.  Testing is cost-effective.  
Treatment is very expensive with a QALY of $66,722 
3 
Physician There is a lack of familiarity with osteoporosis drugs and fear of 
causing patient harm.  Osteoporosis experts frequently 
disagree about guidelines.  Screening for osteoporosis can be 
a lower priority topic in a short outpatient office visit.  Tracking 
progress of measure is easily dose with claims data. 
2 
Society There are both racial and SES differences in testing women for 
osteoporosis following a fracture.  The burden on society is 
financial (very expensive), emotional (stress to family members 
and caregivers), and occupational (affects ability to work). 
3 
* Grading system: 1 – Should not be incented;   3 – may be incented;   5 – Should be incented 
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Table 5: Summary of C13 – Diabetic Eye Exam 
Perspective Summary of Findings Grade* 
Patient Clinically significant outcome for diabetics.  Cost-benefit data 
suggests less frequent visits in well controlled diabetics.  Other 
than the inconvenience of an extra outpatient office visit, no 
harms exist. 
4 
Insurance Provider Large, annually recurring expense.  Treatment is expensive. 1 
Physician No significant barriers to physicians.  Certain sections of the 
US reported long wait times for outpatient eye examinations.  
Easy to track through claims data. 
4 
Society Avoiding blindness is an important societal benefit.  Incidence 
of DR varies between racial groups which is an opportunity for 
targeted interventions to reduce this disparity.  
3 
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Table 6: Summary of C14 – Diabetic Kidney Disease Monitoring 
Perspective Summary of Findings Grade* 
Patient Significant disease burden with effective treatments.  No 
significant barriers or harms. 
4 
Insurance Provider Screening is cheap and avoids ESRD treatment, which is 
extremely expensive.  Screening is cost effective while 
treatment of early disease is cost-saving. 
5 
Physician No barriers identified.  Tracking is easily accomplished through 
claims data. 
4 
Society There is a racial difference in incidence which is likely 
explained by SES. 
4 
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Table 7: Summary of C15 – Diabetic Glycemic Control 
Perspective Summary of Findings Grade* 
Patient Significant disease burden for which there is an effective 
treatment.  Appropriate glycemic control effectively avoids the 
complications of diabetes. The HEDIS HbA1c goal is a safe 
target. 
5 
Insurance Provider The expense of treating diabetes and its complications is 
extremely high.  Treating diabetics in the absence of 
complications is 2.3 times higher than for non-diabetics.  
Treatment is cost-effective due to its ability to halt or slow 
complications 
2 
Physician The HEDIS measure sets a reasonable HbA1c goal.  Barriers 
include clinical inertia and reactive disease management.  
Difficult to track using billing codes and claims data. 
3 
Society Diabetes is a significant societal burden.  Minorities represent a 
disproportionately large portion of the prevalence of diabetes. 
4 
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Table 8: Summary of C16 – Blood Pressure Control 
Perspective Summary of Findings Grade* 
Patient Significant disease burden for which there are effective 
treatments.  Treatment carries a small risk of complications.  
Many barriers resulting from the asymptomatic disease course 
of hypertension. 
4 
Insurance Provider Hypertension has a high and growing prevalence.  Spending 
accounts for 17% of all US expenditures.  Difficulty in 
controlling blood pressure in those with severe disease carries 
a risk of foregoing emphasis on their treatment in favor of those 
more easily treated to target goals. 
3 
Physician Complexity in making a diagnosis is one barrier encountered by 
physicians.  Non-compliance hinders the physician’s 
achievement of HEDIS goal.  Therapeutic inertia is a barrier.  
Tracking may be difficult using standard ICD 10 codes and 
claims data. 
2 
Society Significant societal burden.  There is a racial disparity in the 
prevalence of hypertension.  The burden that the African-
American community bears from hypertension is 
disproportionately high. 
4 
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Table 9: Summary of C17 – Rheumatoid Arthritis Management 
Perspective Summary of Findings Grade* 
Patient Very significant health burden.  Causes disability.  Numerous 
extra-articular complications are possible.  Although treatments 
are effective, they have rare but serious side effects.  Barriers 
include difficulty in attributing symptoms to RA, delaying 
diagnosis.  Poor compliance rates in some studies. 
5 
Insurance Provider Treatment is very expensive and the price of medications has 
recently increased.  Not cost-effective.   
2 
Physician Non-compliance is a barrier to a physician achieving the HEDIS 
goal.  There is room to grown in assuring better compliance in 
the future.  Measure is easily tracked through claims data. 
3 
Society Significant societal burden.  Potential for steep decline is 
quality-of-life for immediate family and community.  Financially 
expensive to purchase medications (co-pay).  Economic losses 
due to disability. 
4 
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Table 10: Results of Clinical HEDIS Measures by Perspectives 
 
 Perspectives 




C01 – Breast Cancer Screening 2 2 3 4 
C02 – Colorectal Cancer Screening 4 3 3 5 
C12 – Osteoporosis Management 4 3 2 3 
C13 – Diabetic Eye Exam 4 1 4 3 
C14 – Diabetic Kidney Disease Monitoring 4 5 4 4 
C15 – Diabetic Glycemic Control 5 2 3 4 
C16 – Blood Pressure Control 4 3 2 4 
C17 – Rheumatoid Arthritis Management 5 2 3 4 
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Limited Systematic Review of the Literature: Are HEDIS Measures for Diabetes Cost-Effective 
Introduction 
   Higher costs are usually associated with better quality.  This underlying belief extends to health 
care where there is an underlying belief that better medical care results from the greater value provided 
by higher costs.1  However, due to increasing financial constraints, the health care climate today 
attempts to achieve both high quality and low cost by using effective procedures and highly trained 
medical providers within efficient health plans.2  Previous cost-effect analyses within the medical 
literature have yielded mixed results.  While some systems have shown that quality and cost can have a 
positive relationship, some show no effect on quality due to costs3, and others a negative or inverse 
effect.4 
 The challenge of achieving higher quality at a lower cost is especially relevant to care for 
diabetes.  Diabetes is one of the most prevalent chronic diseases within the United States and is 
associated with some of the most cost-consuming complications.5  Persons with diabetes comprise a 
small portion of the US population while accounting for a large portion of health care expenditures.  The 
per-capita costs consumed by diabetics are 2.5 times higher than for those without diabetes.6  These 
negative economic trends are well recognized prompting greater emphasis on preventive and 
maintenance care for those with diabetes.  This emphasis has yielded positive trends but even with 
today’s increased focus on preventive care, less than 75% of diabetics meet their preventive medical 
goals.7   
 To address these and other chronic disease concerns, the National Committee for Quality 
Assurance (NCQA) has established the Health Effectiveness Data and Information Set (HEDIS), a measure 
used to institute standardized protocols by which disease processes are monitored and treated.  These 
measures are used to grade and evaluate the disease management services provided by managed 
  Kus 
50 
 
health care plans.  Cost-effectiveness is a key part of the evidence-based rationale of HEDIS measures 
and the NCQA has selected performance measures that “encourage the use of cost-effective activities 
and/or discourage the use of activities that have low cost-effectiveness.”8,9   
 The current HEDIS measures for diabetic care are listed in Appendix Table 1.  They include 
annual monitoring of Hemoglobin A1c (HbA1c), providing adequate blood pressure control, and 
screening for retinopathy and nephropathy.  A managed care plan incurs direct and indirect costs 
implementing these measures.  Direct costs include outpatient office visits, laboratory expenses, and 
specialist visits for retinopathy screening.  Indirect costs include administrative costs to implement and 
monitor the program, incentives provided to physicians to encourage program use, and outreach costs 
used to inform their diabetic members of services when they are due.  The measured benefits of 
diabetic HEDIS guidelines are analyzed by the changes in spending on outpatient visits, disease 
management services, inpatient encounters, surgical procedures, and pharmacy costs. 
Appendix Table 1: Current HEDIS measures for diabetes 
2016 HEDIS measures for diabetes* 
1. Hemoglobin A1c (HbA1c) testing annually 
 HbA1c poor control >9 
 HbA1c control <8 
2. BP control, <140/90 
3. Eye exam (retinal) performed 
4. Medical attention for nephropathy 
* The percentage of members 18 to 75 years of age with diabetes 
(either type 1 or type 2) who had each of the following during the 
measurement year. 
 
 In order to evaluate the cost-effectiveness of the HEDIS measures for diabetes, I conducted a 
systematic review of the literature on managed health plans focused on the relationship between the 
level of HEDIS measure implementation and the resulting costs of services provided.  The costs of 
services are divided into outpatient, inpatient, surgical/procedure, disease management, and pharmacy.  
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The goal of this systematic review is to assess whether higher rates of HEDIS compliance result in lower 
healthcare spending in these areas.  Health plan data will be analyzed for expenditures/resource 
utilization compared to the degree of adherence to HEDIS measures.  Study designs include cohort 
studies, randomized trials, and cross-sectional studies. 
 
Methods 
 The scope of this systematic review is an assessment of literature to answer the question, “Are 
HEDIS measures for diabetes cost-effective?”  To limit the heterogeneity of the studies found, the 
Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement was used to 
guide the approach and reporting of results.10  No published review protocol exists for this topic. 
Data Sources 
 To identify relevant articles, PubMed and Cochrane database engines were searched with 
keywords appropriate for categories of “HEDIS measures” and “cost-effectiveness” from 1995 to 2016.  
The search strategy was initially guided by a health services librarian at the UNC Health Services Library.  
Keywords and MESH headings were generated to create a comprehensive list of search terms relevant 
to the interventions and outcome measures of interest.  Clinicaltrials.gov was also searched for 
unpublished studies yielding no new or unpublished results.  Appendix Table 2 displays the complete 








Appendix Table 2: PubMed/MEDLINE and Cochrane Library Search Terms 




#1 Search (hedis OR "Healthcare Effectiveness Data and Information Set") Filters: Systematic Reviews 18 
#2 Search (hedis OR "Healthcare Effectiveness Data and Information Set") 526 
#3 Search (hedis OR "Healthcare Effectiveness Data and Information Set") AND cost effectiveness 47 
#4 
Search (hedis OR "Healthcare Effectiveness Data and Information Set") AND cost effectiveness AND 
diabetes mellitus 7 
#5 Search hedis AND cost effectiveness 36 
 




#1 Search (hedis OR "Healthcare Effectiveness Data and Information Set") 22 
#2 Search (hedis OR "Healthcare Effectiveness Data and Information Set") AND cost effectiveness 6 
#3 
Search (hedis OR "Healthcare Effectiveness Data and Information Set") AND cost effectiveness AND 
diabetes mellitus 3 
#4 Search hedis AND cost effectiveness 6 
 
Study Eligibility 
 Selection of included studies was based on the inclusion and exclusion criteria in Appendix 
Table 3.  Prospective/retrospective cohort, cross-sectional, and randomized trials published in English 
between January 1, 1995 and April 1, 2016 that analyzed either HEDIS-based diabetic patient care within 
a managed health plan or the plans themselves, and reported the association of the use of HEDIS 
measures for diabetes and cost-effectiveness were considered.  Diabetic patient care studies that 
compared costs of HEDIS-based diabetic care against “traditional care”, not led by HEDIS, were 
accepted.  Studies of health care plans that compared the cost burden of diabetic members within 
health care plans against the degree to which HEDIS measures were accurately followed were accepted.  
Comparators were either patients whose diabetic care was not led by HEDIS measures at all or other 
plans with a greater or lesser degree of adherence to HEDIS measures.  Outcomes included the per-
member-per-month (PMPM) costs to health plans or adjusted resource utilization rates which allow 
better comparisons among regions with wide variations in health care pricing. 
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Appendix Table 3: Inclusion/Exclusion Criteria for Studies of HEDIS Cost-Effectiveness 
 Criteria 
Category Inclusion Exclusion 
Population Commercial and federal health plans 
within the US that submitted HEDIS 
reporting data 
Adults aged 18-75 with diabetes 
participating in managed care plans 
Health plans with missing or 
incomplete HEDIS reporting data 
Interventions Cost-benefit analysis of diabetes 
management using HEDIS measures 
as quality guidelines. 
Resource-use and quality analysis of 
diabetes management using HEDIS as 
quality measure 
HEDIS measures used as a guide to 
diabetic care 
Analysis that does not correlate 
cost or resource utilization 
against quality measures 
Analysis of disease management 
interventions other than diabetes 
Analysis of previously published 
data sets 
Computer-based model analysis 
based on historical data 
Comparators Comprehensive diabetes management 
based on HEDIS guidelines vs 
traditional diabetes management 
Diabetes management analysis before 
and after implementation of HEDIS 
based care model 
Resource utilization/cost and HEDIS 
quality measures between differing 
health plans  
Cost-benefit analysis of single plans 
Diabetics receiving traditional care (not 
guided by HEDIS measures) 
Studies analyzing only one or two 
parts of HEDIS diabetic measures. 
Studies comparing HEDIS measures 
other than diabetes 
Outcomes Cost-benefit analysis of HEDIS 
measures in dollars per benefit 
Cost-benefit analysis of HEDIS 
measures in resource use per benefit 





Studies analyzing data of at least 12 
months 
Studies of data less than 12 months 
Time period Studies published from January 1, 1995 
to April 1, 2016 
Studies published earlier than 1995 
Settings Health care plans within the US  Plans outside of the US 
Language English All other languages 
Admissible 
evidence 
Eligible study designs include 
prospective cohort studies, 
retrospective cohort studies 
Randomized controlled trials 
Cross-sectional studies 
Case-controlled studies 
Case series / Case reports 
Systematic reviews 
Editorials and opinion pieces 
Economic modeling studies 
 




 Studies identified by the database searches were compiled and duplicates removed.  Titles and 
abstracts from all sources identified by the search strategy were reviewed for inclusion and exclusion 
criteria (Appendix Table 3).  Reference lists of selected studies were also searched for additional studies 
not captured by the search strategy.  The hand-selected full-text articles were retrieved and assessed for 
eligibility.  Following title and abstract evaluation, remaining studies were assessed for final eligibility 
Data Items and Extraction 
 The selected studies were analyzed for relevant data which were compiled in an evidence table 
with the following categories: study participants, statistical methods, comparison groups, timeframe of 
study, outcome measures, and results.  Particular attention was placed on the statistical methods used, 
outcome variables, and results.  Statistical methods and outcome variables were considered key 
measures as the cost-benefit association found in each study had to be compared to that of the other 
included studies (i.e. variations from a mean had to be compared to studies reporting raw PMPM cost 
differences or Pearson correlations of HEDIS/cost.)  There is no process in place to confirm or obtain 
data from investigators. 
Risk of Bias 
 Included studies were evaluated for pre-determined outcomes and synthesized in evidence 
tables with the following categories: study design, population/groups evaluated, outcome measures, 
and the duration of observation.  The quality of each included study was assessed using a predefined 
checklist based on STROBE11 and CONSORT12 reporting recommendations.  These recommendations 
include an assessment for selection bias, measurement bias, confounding, random error, and 
generalizability.  Using the results of the quality assessment recommendations, each study was rated as 
good, fair, or poor. 




 The principle summary measures sought from included studies were cost of care and HEDIS 
grading.  The cost of care included individual and aggregate data of outpatient visits, evaluation and 
treatment costs, surgical or procedural costs, inpatient costs, and pharmacy services.  HEDIS data sought 
were either the presence / absence of HEDIS utilization within a health plan or the degree to which 
HEDIS measures for diabetes were adhered to by a health plan.  The cost-benefit results sought from 
included studies were the PMPM costs differences, correlation coefficients of cost and HEDIS adherence 
level, and the observed vs expected costs of plans by the degree to which HEDIS measures were utilized. 
Synthesis of Results 
 A qualitative synthesis of included trials was performed discussing characteristics of included 
populations, interventions, and data analysis methods used to determine the relationship of cost to 
health plans and adherence to HEDIS guidelines.  The synthesis was accomplished by comparing each 
study against the rest for the direction of the cost-benefit analysis, its statistical significance, and 
corresponding conclusions. 
Risk of Bias Across Studies 
 Included studies were analyzed for individual risk of bias determined previously (STROBE and 
CONSORT checklists).  Risks that were present in multiple studies were identified and analyzed further 
for corresponding results of the same studies.  Identified risks of bias among studies were reported in 
the results of this systematic review and analyzed in the discussion. 
Additional Analyses 
 No additional analyses were performed. 
 




 The search of PubMed and Cochrane databases yielded 62 articles (72 articles with 10 duplicates 
removed.)  Additional studies found by reference hand-search (12) resulted in 74 studies for assessment 
using title and abstract data.  Ten studies were selected for full-text review.  Reapplying the eligibility 
criteria resulted in the exclusion of five studies, two of these were excluded due to analysis of previously 
collected data sets with incomplete description of methods.  Three additional studies were excluded for 
cost-benefit evaluation of only a portion of the HEDIS measures.  Five retrospective cohort studies were 
ultimately included.  The PRISMA flow diagram for this systematic review is shown in Appendix Figure 1. 
Study Characteristics 
 Appendix Table 4 displays the characteristics of included studies in context of study design.  Of 
the five studies included, three were based on the annual HEDIS compliance data submitted to 
NCQA.2,13,14  One used internal insurance data from the Geisinger Health Plan,15 and one used data from 
a volunteer cohort of 24 national health plans.16  All studies were retrospective cohorts aiming to find a 
correlation between healthcare expenditures on diabetic care with quality of care, based on adherence 
with the NCQA published HEDIS guidelines for diabetic treatment.2,14-16  The timeframe of three studies 
was 12 months.13,14,16  One study reported claims data spanning 84 months15 while the claims data for 
another covered 36 months.2 
 The participants in one study were matched cohorts within an insurance plan.15  The inclusion 
criteria were members with diabetes who were at least 18 years of age, identified by at least 2 claims for 
diabetes with the International Classification of Diseases, Ninth Revision codes on different days before 
2006.  The intervention group (n=1875) was those who received care at a facility participating in the 
Geisinger diabetes system of care (DSC) bundle, while the control group (n=1875) received care at 
facilities that delivered standard diabetic care without the DSC bundle.  Crossovers, defined as either 
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members who switched care from a DSC-participating facility to one without DSC or the other way 
around were excluded.  Four hundred fifty-four (454) members not receiving DSC care, who were noted 
to be younger with fewer comorbid conditions, could not be matched and were excluded.   
Of the studies based on data from multiple insurance plans, four excluded plans due to missing 
data.2,13,14,16  Two studies excluded plans with less than 400 diabetic members.13,14  One also excluded 
plans with Relative Resource Use (RRU) data that deviated significantly from the mean.13 
 The intervention and outcome variables in the case-matched cohort study were per-member-
per-month (PMPM) dollar values calculated from regression model coefficients based on observed 
versus expected (O/E) cost ratio.  The PMPM value was applied to study groups in 4 categories: 
inpatient, outpatient, professional, and total.15   
Intervention and outcome variables in the studies evaluating data from multiple insurance plans 
used RRU values based on O/E ratios.2,13,14,16  Two studies included correlation coefficients in their 
analysis.2,16  Two others also calculated PMPM expenditure data.13,16  In three of the studies, resulting 
RRU and PMPM values were applied to two study groups: combined medical services (which were 
further broken into inpatient services, evaluation and management services, and surgery and procedure 
services) and ambulatory pharmacy services.2,13,16  One study did not report the sub classification of 
combined medical services reporting using only combined medical and ambulatory pharmacy services.14  
One study further divided its results by plan types (HMO, PPO, POS).2 
 Measures to control for bias included one study using the Simes procedure to minimize random 
errors2 and another, which excluded RRU data significantly deviating from the mean.13 
Risk of Bias 
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 A potential source of bias in the insurance study by Quast2 is selection bias.  One third of the 
annual plan data retrieved from NCQA were excluded for incomplete data.  The exclusion of such a large 
portion of available data risks missing significant trends that may altered the results of this study.  The 
Simes procedure was utilized to reduce the chance of random error. 
In both of their studies of insurance data submitted to the NCQA, Turbyville et al.13,14 reported 
widely variable results which, although equal and reliable, may not be valid.  The exclusion of all plans 
except HMOs also presents a risk of selection bias towards better organized plans which may be more 
likely to yield positive results.   
There is a significant risk of selection bias in the study by Roski et al.16 as all of the 32 insurance 
plans examined were volunteers.  Such a small sample has a relatively high chance of being unreliable.  
Further, 28 of the 32 plans in their study were subsidiary members of one large insurance plan.  The 
study by Maeng et al.15 is also at risk for selection bias as it excluded 454 members that could not be 
matched from the control group.  Those excluded tended to be younger with fewer comorbidities, which 
likely favors the intervention group in the outcomes.  Selected members of the control group also 
tended to receive care at small rural clinics with less access to care than the intervention group, which 
received care in an urban setting.  Lastly, prescription costs, which are responsible for the majority of 
diabetic spending, were not included in the analysis. 
Results of the Individual Studies 
 In the study of the Geisinger DSC intervention by Maeng et al,15 there were no overall cost 
differences in the first year of the intervention.  Every consecutive year, however showed a PMPM cost 
savings.  In first year, the savings amounted to $42 PMPM, a 7.4% (p=0.21) decrease compared to the 
control group.  In year three, costs were $73 PMPM less than those of the control group (12.5% 
decrease, p<0.05).  In year 5, the cost benefit was $124 PMPM less than the control group (18.8% 
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decrease, p<0.01).  The sixth year yielded a savings of $104 (14.7% decrease, p<0.01).  The inpatient care 
spending showed similar trends with a $143 PMPM savings in year 5 (46.8% decrease, p<0.01) and $131 
PMPM savings in year 6 (41.3% decrease, p<0.01).  The outpatient spending increased in the first year of 
the study by $20 PMPM (13%, p<0.05) but subsequently decreased with the greatest savings in year 5 of 
$12 PMPM (6.5% decrease, p=0.37).  Professional services also showed a $15 PMPM increase in the first 
year (9.7%, p<0.01) followed by years of savings with the greatest benefit at year 5 in which it saved $20 
PMPM (11.2% decrease, p<0.05). 
 In his study of the NCQA health plan data, Quast2 found a negative correlation coefficient 
between quality and total cost of care (-0.053, p=0.21), as well as quality and inpatient care (-0.061, 
p=0.08).  A positive correlation was found between quality and surgical/procedure care (0.044, p=0.21), 
as well as between quality and pharmacy care (0.069, p=0.05). 
 In their study of volunteer insurance providers, Roski et al.16 created scatterplots of measuring 
quality of care (HEDIS measures) against the cost of care (RDI or RRU).  They found no correlation in 
total costs, inpatient costs, surgical costs, nor evaluation/management costs.  The scatterplot for 
pharmacy costs however, showed a Pearson’s correlation coefficient of 0.513 (P<0.003).  In a similar 
study of all HMO plans submitting HEDIS related data to NCQA, Turbyville et al14 used scatterplots to 
report the correlation between quality of diabetic care (HEDIS guidelines) and total medical cost (RRU).  
No correlation was observed except in the case of pharmacy spending which revealed a Pearson’s 
coefficient of 0.34 (p<0.05). 
 In their study of the 2007 NCQA plan data from HMOs, Turbyville et al.13 found a negative 
correlation between quality of care (HEDIS adherence) and total overall spending (-0.201, p<0.0008) 
which is driven, mainly, by the quality correlation with surgical services (-0.219, p=0.006) as well as with 
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inpatient services (-0.164, p=0.03).  A positive correlation was observed between quality and pharmacy 
costs (0.162, p=0.03). 
Synthesis of Results 
 Results from included studies are summarized in Appendix Table 5. 
 The study of the Geisinger plan shows that strict adherence to the DSC (driven by the HEDIS 
diabetes guidelines) diminished costs.15  As expected, the initial year tended to increase costs slightly 
but the trend in savings in subsequent years were substantial.  Pharmacy data were not analyzed. 
 Both Quast2 and Turbyville et al13 show a negative correlation between quality and total costs 
driven mostly by the savings in inpatient care costs.  Pharmacy costs showed a positive correlation with 
quality of care in both studies although it was statistically significant in only one of them.  The 
scatterplot analyses of RRU against quality (HEDIS adherence) by Roski et al16 and Turbyville et al14 
revealed no correlation between overall cost of care and quality.  In analysis of the subsets of the total, 
both studies show a positive correlation between quality and pharmacy costs. 
Risk of Bias Across Studies 
 The Geisinger Health Plan study by Maeng et al15 showed significant selection bias in excluding 
healthy controls from matching and in the significantly differing healthcare settings between study 
groups.  Exclusion of pharmacy data also poses a risk to the accuracy of the results as pharmacy 
expenditures tend to be the largest component of spending in diabetic patients.  Although no financial 
interests are claimed, all authors were noted to be employees of the Geisinger Health System. 
 The remaining plans all share significant risks of selection bias as two studies used only HMO-
submitted data13,14, one study included a very small sample of volunteer plans (most of which were part 
  Kus 
61 
 
of a larger, national health plan)16, and the last excluded incomplete plan data which accounted for a 
third of the total available.2   
Except for the Geisinger plan study, all studies also shared the potential of measurement bias.  
Collecting large amounts of data aggregated into one data point carries the risk of missing variations 
within the data and compromising internal validity.2,13,14,16 
Additional Analysis 
 No additional analyses were performed. 
 
Discussion 
Summary of Evidence 
 Of the five studies evaluating diabetic expenditures (RRU) and quality of diabetic care (degree to 
which plan members met the HEDIS guidelines), three showed a trend towards cost effectiveness which 
was statistically significant in two.13,15  Of those two, one was graded as poor quality15 while the other 
provided good evidence.13  The trend towards cost-savings, whether it was significant or not-significant, 
was driven by savings in inpatient care, outpatient care, and, in one study, surgical/procedural care. 
 Differences in diabetes spending among examined health plans varied widely with some studies 
showing little variation16 and others, large variations.14  Pharmacy costs were noted to correlate 
positively with quality of care (degree of adherence to HEDIS measures) in all but one study which did 
not include pharmacy data in its analysis.  These findings indicate cost-ineffectiveness.  This is the only 
finding in this systematic literature review that should be considered reliably accurate and reproducible. 
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 The study with the poorest level of evidence due to several large sources of bias was also the 
study with the most significant cost savings.15  Significant risk of bias was present in the cohort matching 
between the study groups and in the characteristics of the base population of the control group.  The 
outcome variables did not include pharmacy costs, a significant part of diabetes expenditures.  
Nevertheless, the study suggests that a rigorous, physician-led, team approach may produce substantial 
cost savings.  More studies are needed to validate this approach to care. 
Limitations 
 There are several limitations to this systematic review.  A majority of included studies show at 
least some risk of selection bias.  One study excluded healthy controls subjects, two considered only 
HMO claims data, another excluded one third of the available claims data, and the last recruited plan 
data from volunteers.  As is expected, this bias tends away from the mean and toward the hypothesis 
that stricter adherence to HEDIS guidelines saves money.   
This is true also for reporting and publication bias, which may also possible limitations to this 
analysis.  In designing and conducting a study, authors often report outcomes that show the most 
desired effects minimizing outcomes likely to result in null or neutral effects.  Publication bias is an 
extension of reporting bias resulting in publication of data that support those desired effects. 
Another possible limitation in this systematic review is the search strategy.  While “cost-
effectiveness” is a MESH term that includes “cost-benefit” and other similar iterations, the inclusion of 
“HEDIS” in the search strategy may serve to limit retrieval of studies relevant studies.  Conversely, the 
metrics used within the diabetic HEDIS measures could have been individually entered.  Terms such as 
“blood pressure control”, “glycemic control”, “diabetic nephropathy screening”, etc. could have been 
substituted in place of “HEDIS” and may have yielded more studies that met the inclusion criteria. 
 




 This systematic review concludes that available evidence does not support the hypothesis that 
stricter adherence to the NCQA published HEDIS diabetes guidelines will decrease expenditures on 
diabetics.  Results from the studies reviewed are inconsistent.  Although some of the studies showed a 
benefit with statistical significance13,15, others did not.  The only reliably constant finding identified is 
that stricter adherence to the HEDIS data set diabetes guidelines increases pharmacy 
expenditures.2,13,14,16  One study described a rigorous novel approach to standard care of diabetics 
(Geisinger’s DSC) which showed promise of significant cost savings.15  Due to several design flaws, it 
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Appendix Figure 1: PRISMA Systematic Review Flow Chart 
 
 
Define Search Terms 









 (n= 12) 




Full Text Review 
(n= 10) 
5 studies included for article 





























Records Excluded (n= 5) 
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of the relevant measures (n= 3) 
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Appendix Table 4: Characteristics of Included Studies 
Study Study Design Population/ Groups 
Outcome 
variables Time Sources of bias / Weaknesses 
Measures to 
control for bias 
Quality 
Rating 




Diabetic members >18yr 
of Geisinger Health Plan 




using DSC (diabetes 
system of care) a 
bundled diabetic 









costs, and total 
medical costs 










Selection: 454 members in control not 
matched, they tended to be younger 
with less comorbidities 
Crossovers were excluded 
 
Selection: control group tended to get 
care at smaller offices, likely fewer 
resources which favors the 
intervention group. 
 
Measurement: analysis does not 
include the cost of implementing DSC 
and incenting physicians to use it.  
Prescription costs are also excluded 
 
None described  Poor 
Quast T 2015 Retrospective 
cohort 
407 commercial health 
plans who submitted 
annual HEDIS data to 
NCQA  (National 
Committee for Quality 
Assurance). (813 over 3 
years) 
Health plans are 
analyzed for 
quality and 
resource use.  
Reported as a 
correlation of RRU 




Measurement: aggregation of all 
members in a single data point misses 
variations within groups.  Is a poor 
performing plan wasteful or serving a 
population that has a greater need of 
care? 
 
This study demonstrates some 
correlations but cannot elucidate 
causal relationship between quality 
and costs. 
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Groups Outcome variables Time Sources of bias / Weaknesses 
Measures to 







173 HMO plans that 
submitted HEDIS 
data in 2007 met 
criteria 
 




Variation around the mean is 
reported for quality of care, 
medical services, and pharmacy 
services. 
 
Quality of care measures are 
correlated (Pearson) with RRU 
(O/E) on scatterplots for 








Measurement: although the data 
are equal and reliable, validity is 
suspect due to high variation 
 













168 HMO plans that 
submitted HEDIS 
data in 2006 were 
included 
 




Observed to expected utilization 
ratios and PMPM figures by 
HMO.  Figures adjusted by 
diabetes categories.  
 
Correlation between quality 
against resource utilization 
(RRU), and quality against 








External validity: only HMO plans 
were evaluated 
None described Good 





of 24 HMOs and 8 
PPOs. (314,742 
subjects) 
Costs of inpatient care, eval and 
management, surgery-
procedure, and pharmacy.  
Recorded by RDI 
(actual/expected costs) 
 







External validity: small sample of 
volunteers  
Selection: All HMO plans were 
subsidiaries of on large, national 
HMO 
Measurement: 40% of members 
did not have pharmacy benefit 
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Appendix Table 5: Findings from Review of Included Studies of the Cost-Effectiveness of Diabetes HEDIS measures 
Study Participants (n) Intervention Comparison Time Outcome Measures Results 
Maeng et al., 
2016 
1,875 members of 
Geisinger Health Plan 
vs 1,875 contols 
recorded as 178,612 
months vs 158,693 
months for a total of 
337,305 member-
months 
Members using a 
bundled Diabetic 
System of Care 
(DSC) based on 
HEDIS measures 
Diabetic members not 




Inpatient and outpatient 
facility costs, 
professional costs, and 
total medical costs 








Values increased with time in program 
 
13% increase in DSC outpatient costs 




Value decreased with time in program 
 
Quast T., 2015 407 commercial 
health plans who 
submitted annual 
HEDIS data to NCQA  
(National Committee 
for Quality Assurance). 
(813 over 3 years) 
Level of HEDIS 
(defined as 
“quality care”) is 
measured against 
relative resource 
use (RRU) instead 





Aggregate data is 
analyzed for quality of 
care per resources 
used.  Data is reported 







are reported between 
RRU and quality. 
RRU data is aggregated 
into 2 categories: 
1. Medical services 
(inpatient facility use, 
procedures, and 
surgery)  
2. Ambulatory pharmacy 
services 
Quality is defined as 
degree of adherence 
to HEDIS measures. 
There is an overall negative 
correlation of RRU to quality care for 
all diabetic care signaling a net benefit 
of adherence to care  
-0.053 (p=0.13) 
Net loss for surgical care: 
0.044 (p=0.21) 
Net benefit for inpatient care: 
-0.061 (p=0.08) 
Net loss for ambulatory pharmacy: 
0.069 (p=0.05) 
 
There is also a slight net-benefit (not 
statistically significant) for all 
individual plan types. 
 
Roski et al., 
2008 
Volunteer sample of 
24 HMOs and 8 PPOs. 
(314,742 subjects, 18-
75y/o with diabetes 









(CDC), based on 
HEDIS measures 
Aggregate data is 
analyzed for quality of 
care per resources 
used.  Data is reported 
for each plan by 
inpatient care, surgical 







month (PMPM) and RDI 
ratio (actual vs expected 
costs) were reported for 
each health plan 
 
 
No statistically significant correlation 
was found between quality and costs 
for total costs, inpatient costs, surgical 
costs, and evaluation/management 
costs. 
 
Pharmacy costs had a positive Pearson 
correlation of 0.513 (p<0.003) but was 
driven by a few outliers 
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Appendix Table 5 continued: Findings from Review of Included Studies of the Cost-Effectiveness of Diabetes HEDIS measures 
Study Participants (n) Intervention Comparison Time Outcome Measures Results 
Turbyville et al, 
2011 
173 HMO plans that 
submitted HEDIS data 
in 2007 met criteria 










quality of diabetic care 
and RRU were 
correlated for medical 
services and pharmacy 
use. 
Values are also 
distributed around the 
mean to demonstrate 
variation. 
 
12 months of 
claim data 
 Variation around the 
mean is reported for 
quality of care, medical 
services, and pharmacy 
services. 
Quality of care measures 
are correlated with RRU 
on scatterplots to 
determine quality-cost 
ratio 
The correlation of quality to RRU is 
negative signaling a possible net 
benefit of HEDIS measure use 
-0.201 (p<0.008) 
Pharmacy benefit correlation is 
positive signaling better care with 
more utilization 
0.162 (p=0.03) 
Surgical and inpatient services are 
also negative (diminished with 
better care) 
-0.219 (p=0.006) and -0.164 
(p=0.03) 
Turbyville et al, 
2011 
168 HMO plans that 
submitted HEDIS data 





Expected resource use 
rates (based on mean 
within an area) are 
compared to actual 
use (stratified by 
diabetes category).   
Total per-member-
per-month data was 
also recorded 
(PMPM).  Data was 
stratified by region. 
12 months of 
claim data 
Observed to expected 
utilization ratios and 
PMPM figures.  Figures 
adjusted by diabetes 
categories. 
Medical care O/E ratio ranged 
from 0.25 to 2.45 (mean=1) 
PMPM ranged from $174.20 to 
$387.85 
 
Pharmacy use O/E ratio ranged 
from 0.39 to 3.09 (mean=1) 
PMPM ranged from $186.67 to 
$291.88 
 
Pharmacy spending correlates 
with increased quality.   
Rho=0.34, P<0.5 
Medical care shows poor 
correlation on scatterplot. 
 
 
 
